title: Protective effects of aliskiren on ischemia-reperfusion-induced renal injury in rats.
abstract: The protective effect of aliskiren on ischemia-reperfusion (I/R) injury in the heart and brain has been reported. Whether or not this protective effect extends into the alleviation of renal I/R injury is not known. Therefore, we investigated the protective effect of aliskiren in the kidney in this study. Sprague-Dawley rats were randomly divided into four groups: sham control group; sham control with aliskiren pretreatment; I/R group and I/R with aliskiren pretreatment. Aliskiren (3mg/kg) or vehicle was administrated intravenously via vena cava. Blood samples and the left kidneys were then collected to check for renal function, angiotensin II (Ang II), apoptosis and oxidative stress levels. Compared with the sham rats, serum creatinine (SCR) and blood urea nitrogen (BUN) were significantly increased in the I/R rats, accompanied by histopathological damage to the kidney, which included tubular cell swelling, desquamation, and cast formation. There were also more apoptotic cells and leukocyte infiltration in the I/R rats than in the sham rats. Pretreatment with aliskiren ameliorated I/R induced renal injury, i.e. reduced SCR and BUN levels, ameliorated renal histopathological changes, and decreased the apoptosis of cells and leukocyte infiltration in kidney. I/R injury also decreased superoxide dismutase (SOD) and glutathione (GSH-reduced form) levels, which were blocked with the aliskiren pretreatment. Aliskiren pretreatment exerts a protective effect on ischemia/reperfusion injury in the kidney, via amelioration of oxidative stress, and reduction in leukocyte infiltration and cellular apoptosis.
authors.affiliation: Department of Cardiology, Daping Hospital, The Third Military Medical University, Chongqing 400042, China; Chongqing Institute of Cardiology, Chongqing, China.
authors.forename: Zhen
authors.initials: Z
authors.lastname: Wang
authors.forename: Yukai
authors.initials: Y
authors.lastname: Liu
authors.forename: Yu
authors.initials: Y
authors.lastname: Han
authors.forename: Weiwei
authors.initials: W
authors.lastname: Guan
authors.forename: Xun
authors.initials: X
authors.lastname: Kou
authors.forename: Jinjuan
authors.initials: J
authors.lastname: Fu
authors.forename: Di
authors.initials: D
authors.lastname: Yang
authors.forename: Hongmei
authors.initials: H
authors.lastname: Ren
authors.forename: Duofen
authors.initials: D
authors.lastname: He
authors.forename: Lin
authors.initials: L
authors.lastname: Zhou
authors.forename: Chunyu
authors.initials: C
authors.lastname: Zeng
mesh_terms: D000577:Amides / Q000494:pharmacology*; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D019610:Cytoprotection; D005650:Fumarates / Q000494:pharmacology*; D007668:Kidney / Q000166:cytology / Q000187:drug effects* / Q000293:injuries* / Q000502:physiology; D008297:Male; D018384:Oxidative Stress / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000150:complications* / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology
chemical_list: D000577:Amides; D005650:Fumarates; C446481:aliskiren
keywords: Aliskiren; Angiotensin II; Apoptosis; Oxidative stress; Renal ischemia–reperfusion